Optimization of Ra-223 imaging protocol using gamma cameras for therapeutic and prognostic evaluation in prostate cancer patients metastatic to bone treated with Ra-223 dichloride

Optimization of Ra-223 imaging protocol using gamma cameras for therapeutic and prognostic evaluation in prostate cancer patients metastatic to bone treated with Ra-223 dichloride - Optimization of Ra-223 imaging protocol for therapeutic and prognostic evaluation in prostate cancer patients treated with Ra-223

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024274

Enrollment

Registered

2016-10-03

Start date

2016-10-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

castration-resistant prostate cancer

Interventions

Prostate cancer patients treated with Ra-223 will receive Ra-223 imaging tests using gamma cameras if written informed consent is obtained.

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: (1) Castration-resistant prostate cancer patients with bone metastasis aged 20 years or over (2) Patients who were considered eligible for Ra-223 therapy on the basis of the judgment of urologists (3) Patients who gave written informed consent to this study

Exclusion criteria

Exclusion criteria: (1) Patients who refused to give written informed consent to this study (2) Patients who are too claustrophobic to lie down on the bed of gamma cameras in spite of the open nature of this imaging device

Design outcomes

Primary

Measure	Time frame
Establishment of the optimal imaging protocol of Ra-223 using gamma cameras in terms of quantitative accuracy and the relationship between the quantitative values of Ra-223 and therapeutic outcome or prognosis	—

Countries

Japan

Contacts

Public ContactTADAKI Nakahara

Keio University School of Medicine Department of Diagnostic Radiology

nakahara@rad.med.keio.ac.jp03-3353-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026